7+3 + quizartinib induction + maintenance for FLT3-ITD+ AML 1L

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CYTARABINE` `DRUG-DAUNORUBICIN` `DRUG-QUIZARTINIB`

ID	`REG-QUIZARTINIB-7-3`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ELN-AML-2022` `SRC-NCCN-AML-2025` `SRC-QUANTUM-FIRST-ERBA-2023`

Notes

Approved 2023 for newly-dx FLT3-ITD+ AML aged 18-75. Median OS 31.9 vs 15.1 mo per QuANTUM-First. Quizartinib does NOT cover FLT3-TKD/D835 mutations — for those use midostaurin + 7+3 or refer to clinical trial. Consider alloHCT in CR1 for FLT3-ITD with high allelic burden (NPM1-wt). STUB — pending Co-Lead sign-off.

Used By

Indication

IND-AML-1L-QUIZARTINIB-FLT3ITD - IND-AML-1L-QUIZARTINIB-FLT3ITD